Lenacapavir, a long-acting injectable PrEP, requires two injections annually, marking a significant advancement in HIV ...

Lenacapavir received approval from the U.S. Food and Drug Administration (FDA) in June 2025 and has subsequently been endorsed in the updated World Health Organisation (WHO) guidelines on long-acting ...

LONDON — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission. In a statement ...

The U.S. Food and Drug Administration (FDA) recently approved a groundbreaking new option for preventing HIV, the virus that causes AIDS. The injectable drug lenacapavir was approved in June and is ...

FAYETTEVILE, N.C. (WTVD) -- Fayetteville native John Rowell calls the FDA's approval of the first injectable treatment for HIV pre-exposure prevention, PrEP, "monumental." The FDA said the injectable ...

AUSTIN (KXAN) — Advocates for HIV prevention are calling a newly approved injectable medication a major step in eliminating the spread of the virus. This summer, the FDA approved Gilead’s lenacapavir, ...

A study suggests twice-yearly Yeztugo offers HIV prevention without adversely affecting gender-affirming care.

HOUSTON — The fight against HIV has come a long way, and new advancements in prevention are changing the game. One of the latest breakthroughs is a long-lasting injectable form of PrEP (pre-exposure ...

Doctors at DAP Health have begun administering a new twice-a-year injectable HIV prevention medication, which was approved by the Food and Drug Administration in June. Gilead's drug lenacapavir ...

LONDON — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus’ transmission. In a statement ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found. UCSF researchers are the first to demonstrate that the approach works for the ...

BOSTON — HIV can be suppressed when the long-acting combination of cabotegravir plus rilpivirine (Cabenuva, ViiV Healthcare) is administered every 8 weeks, according to data from the ATLAS-2M study, ...